362 related articles for article (PubMed ID: 17504161)
1. Targeting the ubiquitin-proteasome pathway in cancer therapy.
Ishii Y; Waxman S; Germain D
Anticancer Agents Med Chem; 2007 May; 7(3):359-65. PubMed ID: 17504161
[TBL] [Abstract][Full Text] [Related]
2. The proteasome: a novel target for anticancer therapy.
Montagut C; Rovira A; Albanell J
Clin Transl Oncol; 2006 May; 8(5):313-7. PubMed ID: 16760005
[TBL] [Abstract][Full Text] [Related]
3. [Proteasome inhibitor].
Yamamura M; Hirai T; Yamaguchi Y
Nihon Rinsho; 2010 Jun; 68(6):1079-84. PubMed ID: 20535959
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.
Chen D; Frezza M; Schmitt S; Kanwar J; Dou QP
Curr Cancer Drug Targets; 2011 Mar; 11(3):239-53. PubMed ID: 21247388
[TBL] [Abstract][Full Text] [Related]
5. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
Ludwig H; Khayat D; Giaccone G; Facon T
Cancer; 2005 Nov; 104(9):1794-807. PubMed ID: 16178003
[TBL] [Abstract][Full Text] [Related]
6. The ubiquitin proteasome pathway from bench to bedside.
Orlowski RZ
Hematology Am Soc Hematol Educ Program; 2005; ():220-5. PubMed ID: 16304384
[TBL] [Abstract][Full Text] [Related]
7. Proteasome inhibition in the treatment of cancer.
Richardson PG; Mitsiades C; Hideshima T; Anderson KC
Cell Cycle; 2005 Feb; 4(2):290-6. PubMed ID: 15655370
[TBL] [Abstract][Full Text] [Related]
8. Preclinical and clinical development of the proteasome inhibitor bortezomib in cancer treatment.
Montagut C; Rovira A; Mellado B; Gascon P; Ross JS; Albanell J
Drugs Today (Barc); 2005 May; 41(5):299-315. PubMed ID: 16082428
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib for multiple myeloma.
Popat R; Joel S; Oakervee H; Cavenagh J
Expert Opin Pharmacother; 2006 Jul; 7(10):1337-46. PubMed ID: 16805719
[TBL] [Abstract][Full Text] [Related]
10. Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.
Dou QP; Zonder JA
Curr Cancer Drug Targets; 2014; 14(6):517-36. PubMed ID: 25092212
[TBL] [Abstract][Full Text] [Related]
11. Targeting the proteasome pathway.
Tsukamoto S; Yokosawa H
Expert Opin Ther Targets; 2009 May; 13(5):605-21. PubMed ID: 19397479
[TBL] [Abstract][Full Text] [Related]
12. Proteasome: an emerging target for cancer therapy.
Zavrski I; Jakob C; Schmid P; Krebbel H; Kaiser M; Fleissner C; Rosche M; Possinger K; Sezer O
Anticancer Drugs; 2005 Jun; 16(5):475-81. PubMed ID: 15846112
[TBL] [Abstract][Full Text] [Related]
13. The development of proteasome inhibitors as anticancer drugs.
Adams J
Cancer Cell; 2004 May; 5(5):417-21. PubMed ID: 15144949
[TBL] [Abstract][Full Text] [Related]
14. The proteasome as a potential target for novel anticancer drugs and chemosensitizers.
Landis-Piwowar KR; Milacic V; Chen D; Yang H; Zhao Y; Chan TH; Yan B; Dou QP
Drug Resist Updat; 2006 Dec; 9(6):263-73. PubMed ID: 17197231
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib: a new pro-apoptotic agent in cancer treatment.
Russo A; Bronte G; Fulfaro F; Cicero G; Adamo V; Gebbia N; Rizzo S
Curr Cancer Drug Targets; 2010 Feb; 10(1):55-67. PubMed ID: 20088794
[TBL] [Abstract][Full Text] [Related]
16. Proteasome inhibitors in the clinical setting: benefits and strategies to overcome multiple myeloma resistance to proteasome inhibitors.
Cheriyath V; Jacobs BS; Hussein MA
Drugs R D; 2007; 8(1):1-12. PubMed ID: 17249845
[TBL] [Abstract][Full Text] [Related]
17. Sequencing bortezomib with chemotherapy and targeted agents.
Adjei AA
Clin Lung Cancer; 2005 Oct; 7 Suppl 2():S56-8. PubMed ID: 16250928
[TBL] [Abstract][Full Text] [Related]
18. Curcusone D, a novel ubiquitin-proteasome pathway inhibitor via ROS-induced DUB inhibition, is synergistic with bortezomib against multiple myeloma cell growth.
Cao MN; Zhou YB; Gao AH; Cao JY; Gao LX; Sheng L; Xu L; Su MB; Cao XC; Han MM; Wang MK; Li J
Biochim Biophys Acta; 2014 Jun; 1840(6):2004-13. PubMed ID: 24534329
[TBL] [Abstract][Full Text] [Related]
19. Targeting apoptosis in solid tumors: the role of bortezomib from preclinical to clinical evidence.
Russo A; Fratto ME; Bazan V; SchirĂ³ V; Agnese V; Cicero G; Vincenzi B; Tonini G; Santini D
Expert Opin Ther Targets; 2007 Dec; 11(12):1571-86. PubMed ID: 18020979
[TBL] [Abstract][Full Text] [Related]
20. [A new therapy with bortezomib, an oncologic medicinal product of the year 2004].
Monneret C; Buisson JP; Magdelenat H
Ann Pharm Fr; 2005 Sep; 63(5):343-9. PubMed ID: 16385784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]